

# CITATION REPORT

List of articles citing

**Systematic review: adherence issues in the treatment of ulcerative colitis**

**DOI: 10.1111/j.1365-2036.2006.02809.x**

**Alimentary Pharmacology and Therapeutics, 2006, 23, 577-85**

**Source:** <https://exaly.com/paper-pdf/40425758/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
247	Seguridad de los tratamientos en la enfermedad inflamatoria intestinal. <b>2006</b> , 29, 45-51		0
246	Medication-taking behavior in a cohort of patients with inflammatory bowel disease. <b>2006</b> , 51, 2165-9		95
245	Do black and Hispanic Americans with inflammatory bowel disease (IBD) receive inferior care compared with white Americans? Uneasy questions and speculations. <b>2007</b> , 102, 1343-9		34
244	Diagnosis and management of inflammatory bowel disease. <b>2007</b> , 5, 289-296		4
243	"Take your medicine": nonadherence issues in patients with ulcerative colitis. <b>2007</b> , 30, 212-7; quiz 218-9		8
242	Drug insight: aminosalicylates for the treatment of IBD. <b>2007</b> , 4, 160-70		98
241	Current medical therapy for chronic inflammatory bowel diseases. <b>2007</b> , 87, 697-725		15
240	Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. <b>2007</b> , 39, 524-9		23
239	Mesalamine. <b>2007</b> , 42, 543-552		1
238	Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. <b>2007</b> , 13, S2-12; quiz S13-4		17
237	[Compliance to drug therapy in inflammatory bowel diseases outpatients from a university hospital]. <b>2007</b> , 44, 289-96		13
236	5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. <b>2007</b> , 13, 1009-15		22
235	Nonadherence in inflammatory bowel disease: results of factor analysis. <b>2007</b> , 13, 1244-9		106
234	Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. <b>2007</b> , 7, 20		38
233	Adherence to thiopurine treatment in out-patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 217-25	6.1	52
232	Serie: psychologische interventies bij somatische aandoeningen. <b>2007</b> , 35, 77-87		
231	Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. <b>2007</b> , 24, 826-40		40

230	The impact of medication regimen factors on adherence to chronic treatment: a review of literature. <b>2008</b> , 31, 213-24		373
229	Age and body satisfaction predict diet adherence in adolescents with Inflammatory Bowel Disease. <b>2008</b> , 15, 278-86		5
228	Quality of life of patients with ulcerative colitis: past, present, and future. <b>2008</b> , 14, 554-65		96
227	Forecasting the recurrence of ulcerative colitis: can U.C. the future?. <b>2008</b> , 14, 422-4		2
226	Review article: improving adherence to medication in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27 Suppl 1, 9-14	6.1	44
225	Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 1157-66	6.1	87
224	Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 663-73	6.1	54
223	Strategies to improve adherence and outcomes in patients with ulcerative colitis. <b>2008</b> , 68, 2601-9		26
222	[Inflammatory bowel disease. Should aminosalicylates be administered in a single daily dose in ulcerative colitis?]. <b>2008</b> , 31, 396-7		
221	Mesalamine with MMX technology for the treatment of ulcerative colitis. <b>2008</b> , 2, 299-314		8
220	Multi-matrix system mesalamine: to use or not to use. <b>2008</b> , 42, 265-9		9
219	Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. <i>Gut</i> , <b>2008</b> , 57, 893-902	19.2	117
218	MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. <b>2008</b> , 9, 1049-58		14
217	Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?. <b>2008</b> , 42, 338-44		26
216	The challenge of compliance and persistence: focus on ulcerative colitis. <b>2008</b> , 14, s2-12; quiz s13-5		23
215	Mesalazine for ulcerative colitis: evidence for use. <b>2009</b> , 7, 352-356		
214	[Non-adherence to the therapy in Crohn's disease patients: prevalence and risk factors]. <b>2009</b> , 46, 183-9		6
213	A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. <b>2009</b> , 1, CMT.S38		0

212	Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. <b>2009</b> , 80, 241-6		15
211	New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. <b>2009</b> , 66, 451-7		7
210	Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. <i>Gut</i> , <b>2009</b> , 58, 233-40	19.2	125
209	Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. <b>2009</b> , 15, 1-8		64
208	Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. <b>2009</b> , 15, 581-8		71
207	Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. <b>2009</b> , 15, 837-44		196
206	Strategies to improve quality of life in adolescents with inflammatory bowel disease. <b>2009</b> , 15, 1755-64		66
205	Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 247-57	6.1	136
204	Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 459-69	6.1	47
203	A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol). <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 1193-201	6.1	6
202	High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 864-72	6.1	12
201	Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 908-18	6.1	64
200	An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 1118-27	6.1	49
199	An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. <b>2009</b> , 3, 32-7		9
198	Indicator Reagents. <b>2009</b> ,		
197	[Treatment adherence in inflammatory bowel disease. Strategies for improvement]. <b>2009</b> , 32 Suppl 2, 31-6		
196	Ulcerative colitis: current medical therapy and strategies for improving medication adherence. <b>2009</b> , 21, 1-8		15
195	Importance of mucosal healing in ulcerative colitis. <b>2010</b> , 16, 338-46		161

194	Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. <b>2010</b> , 16, 1947-56		40
193	Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. <b>2010</b> , 81, 182-6		35
192	Moxibustion for ulcerative colitis: a systematic review and meta-analysis. <b>2010</b> , 10, 36		35
191	Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis. <b>2010</b> , 22, 586-92		1
190	Systematic review: fatigue in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 131-43	6.1	132
189	Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence. <b>2010</b> , 1, 57-63		3
188	A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. <b>2010</b> , 13, 148-61		17
187	Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. <b>2010</b> , 1, 107-14		6
186	Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases. <b>2010</b> , 85, 40-52		13
185	Mid-level providers in gastroenterology. <b>2010</b> , 105, 246-51		13
184	Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. <b>2010</b> , 105, 525-39		187
183	Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. <b>2010</b> , 6, 677-82		6
182	Inflammatory bowel disease. <b>2010</b> , 19, 301-18, ix		42
181	Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. <b>2010</b> , 39, 559-99		32
180	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. <b>2010</b> , 4, 171-5		23
179	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: an IG-IBD study. <b>2010</b> , 4, 291-300		17
178	Factors that modify therapy adherence in patients with inflammatory bowel disease. <b>2010</b> , 4, 422-6		25
177	Assessing Drug Treatment Preferences of Patients with Crohn's Disease. <b>2010</b> , 3, 113-123		12

176	Inflammatory bowel disease. <b>2011</b> , 58, 903-20, x-xi		15
175	Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. <b>2011</b> , 5, 111-6		5
174	Current practice and perception of screening for medication adherence in inflammatory bowel disease. <b>2011</b> , 45, 878-82		27
173	Reminder packaging for improving adherence to self-administered long-term medications. <i>The Cochrane Library</i> , <b>2011</b> , CD005025	5.2	76
172	Le plus ça change: why we need better biomarkers to predict outcomes in ulcerative colitis. <b>2011</b> , 26, 1085-6		2
171	Review article: defining remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 113-24	6.1	145
170	Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1115-22	6.1	19
169	Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. <b>2011</b> , 56, 3112-21		16
168	Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. <b>2011</b> , 56, 3463-70		22
167	Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. <b>2011</b> , 11, 157		13
166	Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. <b>2011</b> , 17, 599-604		72
165	Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. <b>2011</b> , 17, 1270-6		58
164	Which oral aminosalicylate for ulcerative colitis?. <b>2011</b> , 49, 8-12		1
163	Optimization of conventional therapy in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2011</b> , 8, 646-56	24.2	48
162	Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. <b>2011</b> , 106, 2070-7; quiz 2078		47
161	[Topical therapy of ulcerative colitis]. <b>2011</b> , 100, 1413-24		1
160	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <b>2012</b> , 10, CD000544		101
159	Ulcerative Colitis. <b>2012</b> , 1217-1229		

158	Mesalamine in the treatment and maintenance of remission of ulcerative colitis. <b>2012</b> , 5, 113-23	74
157	Herbal medicine in the treatment of ulcerative colitis. <b>2012</b> , 18, 3-10	79
156	Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <b>2012</b> , 55, 93-108	80
155	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <b>2012</b> , 10, CD000543	90
154	Difficulties in taking aminosalicylates for patients with ulcerative colitis. <b>2012</b> , 35, 24-31	10
153	Ulcerative colitis from patients' viewpoint: a review of two Internet surveys. <b>2012</b> , 35, 54-63	10
152	Ulcerative colitis. <b>2012</b> , 380, 1606-19	1036
151	Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. <b>2012</b> , 41, 443-62	23
150	Multi-Matrix System (MMX <sup>®</sup> ) mesalamine for the treatment of mild-to-moderate ulcerative colitis. <b>2012</b> , 13, 2225-32	2
149	Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. <b>2012</b> , 12, 108	47
148	Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. <b>2012</b> , 12, 132	32
147	The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis. <b>2012</b> , 30 Suppl 2, 55-9	13
146	Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. <b>2012</b> , 44, 206-10	36
145	Gastrointestinal Diseases. <b>2012</b> ,	
144	Topical therapies in inflammatory bowel disease. <b>2012</b> , 86 Suppl 1, 36-44	22
143	Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. <b>2012</b> , 18, 701-12	22
142	Optimizing management of Crohn's disease within a project management framework: results of a pilot study. <b>2012</b> , 18, 254-60	31
141	Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. <b>2012</b> , 18, 1026-33	26

140	One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. <b>2012</b> , 18, 1885-93		17
139	Risk factors of anxiety and depression in inflammatory bowel disease. <b>2012</b> , 18, 2086-91		121
138	Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. <b>2012</b> , 18, 1785-94		37
137	Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 342-9	6.1	79
136	Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 126-34	6.1	9
135	Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. <b>2013</b> , 19, 301-8		3
134	Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. <b>2013</b> , 13, 23		36
133	Considerations of traditional Chinese medicine as adjunct therapy in the management of ulcerative colitis. <b>2013</b> , 44, 274-83		42
132	A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. <b>2013</b> , 108, 249-55		16
131	National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey. <b>2013</b> , 7, 497-509		18
130	Ulcerative colitis. <b>2013</b> , 346, f432		99
129	Topische Therapie bei chronisch-entzündlichen Darmerkrankungen. <b>2013</b> , 8, 197-204		1
128	Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 531-8	6.1	31
127	Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 767-75	6.1	45
126	[110th Scientific Meeting of the Japanese Society of Internal Medicine: Invited lecture: 4. Recent progress of research and clinics in inflammatory bowel disease]. <b>2013</b> , 102, 2195-213		
125	[The association between the therapeutic agent and the compliance of the patients with inflammatory bowel diseases]. <b>2013</b> , 61, 313-8		
124	Ulcerative colitis and patient self-management. <b>2014</b> , 25, 382-386		
123	Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. <b>2014</b> , 20, 309-14		10



122	Treatment of inflammatory bowel disease: is your patient at risk of non-adherence?. <b>2014</b> , 27, 576-80	4
121	Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. <b>2014</b> , 109, 1850-5	17
120	Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. <b>2014</b> , 49, 662-73	12
119	eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. <b>2014</b> , 20, 2276-85	61
118	Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis. <b>2014</b> , 20, 1399-406	5
117	Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. <b>2014</b> , 20, 82-91	16
116	Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey. <b>2014</b> , 26, 288-94	30
115	Topische Therapie bei chronisch-entzündlichen Darmerkrankungen. <b>2014</b> , 36, 353-358	2
114	Medication adherence part two: predictors of nonadherence and adherence. <b>2014</b> , 26, 225-232	20
113	pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model. <b>2014</b> , 103, 687-96	56
112	Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. <b>2014</b> , 8, 357-62	7
111	Nanotechnology in the treatment of inflammatory bowel diseases. <b>2014</b> , 8, 903-18	48
110	Topical therapy is underused in patients with ulcerative colitis. <b>2014</b> , 8, 56-63	43
109	Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. <b>2015</b> , 94, e1677	71
108	A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. <b>2015</b> , 32, 983-1028	101
107	Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. <b>2015</b> , 21, 1719-36	25
106	New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?. <b>2015</b> , 21, 2948-57	1
105	Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. <b>2015</b> , 21, 703-15	37

104	Urinary Excretion Levels of MMX-Mesalazine as a Tool to Assess Non- Adherence. <b>2015</b> , 6,		3
103	QIPP and ulcerative colitis: Optimising the management of patients in primary care. <b>2015</b> , 21, 465-468		
102	Psychosocial Support of the Inflammatory Bowel Disease Patient. <b>2015</b> , 95, 1281-93, vii-viii		7
101	Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?. <b>2015</b> , 17, 600-11		4
100	Modern Management of Cancer of the Rectum. <b>2015</b> ,		1
99	Angelica acutiloba Kitagawa Extract Attenuates DSS-Induced Murine Colitis. <b>2016</b> , 2016, 9275083		3
98	Importance of Patients' Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease. <b>2016</b> , 50, 157-62		20
97	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2016</b> , CD000544	5.2	60
96	Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. <b>2016</b> , 50, 318-25		15
95	Adherence to a predefined vaccination program in patients with inflammatory bowel disease. <b>2016</b> , 39, 385-392		1
94	Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. <b>2016</b> , 18, O214-23		17
93	Adherence to a predefined vaccination program in patients with inflammatory bowel disease. <b>2016</b> , 39, 385-92		4
92	Flaxseed lignan secoisolariciresinol diglucoside ameliorates experimental colitis induced by dextran sulphate sodium in mice. <b>2016</b> , 26, 187-195		8
91	Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. <b>2016</b> , 28, 1313-9		17
90	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2016</b> , 4, CD000543	5.2	51
89	Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. <b>2016</b> , 10, 925-33		20
88	Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. <b>2016</b> , 128, 273-81		8
87	Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. <b>2016</b> , 61, 358-70		26

86	Telemanagement of Inflammatory Bowel Disease. <b>2016</b> ,	2
85	Difficulties in Performing Mesalazine Enemas and Factors Related to Discontinuation Among Patients With Ulcerative Colitis. <b>2017</b> , 40, 101-108	2
84	2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial. <b>2017</b> , 23, 822-832	17
83	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. <b>2017</b> , 23, 833-839	59
82	The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. <b>2017</b> , 23, 1011-1018	61
81	Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-induced Colitis. <b>2017</b> , 23, 753-766	51
80	CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. <b>2017</b> , 23, 804-813	11
79	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. <b>2017</b> , 23, 570-577	58
78	The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. <b>2017</b> , 11, 33-41	7
77	Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis. <b>2017</b> , 95, 438-450	29
76	Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2017</b> , 2017, 6019530	2.3 6
75	Adherence in ulcerative colitis: an overview. <b>2017</b> , 11, 297-303	31
74	Predictors and clinical outcomes of follow-up loss in patients with inflammatory bowel disease. <b>2018</b> , 33, 1834-1838	3
73	Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis. <b>2018</b> , 63, 1756-1762	36
72	Vinpocetine Ameliorates Acetic Acid-Induced Colitis by Inhibiting NF- $\kappa$ B Activation in Mice. <b>2018</b> , 41, 1276-1289	15
71	Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. <b>2018</b> , 24, 450-463	8
70	Therapeutic roles of polysaccharides from <i>Dendrobium Officinale</i> on colitis and its underlying mechanisms. <b>2018</b> , 185, 159-168	57
69	Alternative foaming agents for topical treatment of ulcerative colitis. <b>2018</b> , 106, 1448-1456	9

68 Colitis ulcerosa. **2018**, 22, 1-8

67	Patient Preference and Physician Perceptions of Patient Preference for Oral Pharmaceutical Formulations: Results from a Real-Life Survey. <b>2018</b> , 3, 43-51		3
66	Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. <b>2018</b> , 1, 129-134		6
65	Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	21
64	Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 5760849	2.8	3
63	Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. <b>2018</b> , 12, 883-897		13
62	Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. <b>2018</b> , 21, 869-877		1
61	De-escalation of IBD Therapy: When, Who, and How?. <b>2019</b> , 1,		1
60	The Development of a Screening Tool to Identify and Classify Nonadherence in Inflammatory Bowel Disease. <b>2019</b> , 1,		0
59	Maneuvering Clinical Pathways for Ulcerative Colitis. <b>2019</b> , 21, 52		2
58	When managing ulcerative colitis in older patients, understanding their overall health profile is key. <b>2019</b> , 35, 369-373		
57	Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease. <b>2019</b> , 3, 302-309		6
56	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <b>2019</b> , 37, 266-283		29
55	ACG Clinical Guideline: Ulcerative Colitis in Adults. <b>2019</b> , 114, 384-413		458
54	Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients. <b>2019</b> , 17, 419-428.e6		38
53	Treatment Adherence in Patients with Ulcerative Colitis Is Dependent on the Formulation of 5-Aminosalicylic Acid. <b>2019</b> , 99, 133-139		2
52	Efficacy of co-administration of modified apple polysaccharide and probiotics in guar gum-Eudragit S100 based mesalamine mini tablets: A novel approach in treating ulcerative colitis. <b>2019</b> , 126, 427-435		20
51	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. <b>2019</b> , 156, 748-764		92

50	AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. <b>2019</b> , 156, 769-808.e29		61
49	Management of Ulcerative Colitis in the Elderly. <b>2019</b> , 36, 13-27		3
48	A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis. <b>2020</b> , 144, 111628		4
47	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2020</b> , 8, CD000543	5.2	9
46	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2020</b> , 8, CD000544	5.2	11
45	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
44	Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 73-84	6.1	11
43	Adherence to Azathioprine/6-Mercaptopurine in Children and Adolescents with Inflammatory Bowel Diseases: A Multimethod Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 2020, 9562192	2.8	1
42	Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228256	3.7	4
41	Nanogels of a Succinylated Glycol Chitosan-Succinyl Prednisolone Conjugate: Release Behavior, Gastrointestinal Distribution, and Systemic Absorption. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
40	Thiopurine adherence: high prevalence with low impact in UC outcomes. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2021</b> ,	0.9	
39	Sulfated polysaccharides from pacific abalone attenuated DSS-induced acute and chronic ulcerative colitis in mice regulating intestinal micro-ecology and the NF-B pathway. <i>Food and Function</i> , <b>2021</b> , 12, 11351-11365	6.1	5
38	Questionnaire survey to identify meal habits which influence adherence to oral 5-aminosalicylic acid regimens in patients with ulcerative colitis. <i>Journal of Pharmacy Practice and Research</i> , <b>2021</b> , 51, 374	0.7	0
37	Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1891-1900 <sup>2-5</sup>		3
36	5-Aminosalicylate Therapy. 317-328		1
35	Self-Management Techniques in IBD. <b>2016</b> , 55-70		6
34	Ulcerative Proctitis and Anorectal Crohn's Disease. <b>2019</b> , 531-554		1
33	Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. <i>Gut</i> , <b>2021</b> , 70, 677-686	19.2	14

32	Adherence to secondary prevention strategies after stroke: A review of the literature. <i>British Journal of Neuroscience Nursing</i> , <b>2010</b> , 6, 282-286	0.1	5
31	Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183119	3.7	11
30	Nonadherence to Medication in Inflammatory Bowel Disease: Rate and Reasons. <i>Middle East Journal of Digestive Diseases</i> , <b>2016</b> , 8, 116-21	1.1	9
29	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. <i>Health Technology Assessment</i> , <b>2016</b> , 20, 1-326	4.4	32
28	Medication-Related Knowledge and Medication Adherence in Pediatric and Adolescent Patients with Inflammatory Bowel Disease. <i>Journal of Korean Medical Science</i> , <b>2020</b> , 35, e92	4.7	7
27	Understanding of chemoprophylaxis and concordance in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 578-82	5.6	4
26	Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 3467-78	5.6	23
25	Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 9468-75	5.6	34
24	Transition clinic attendance is associated with improved beliefs and attitudes toward medicine in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 5405-5411	5.6	18
23	Coordinated Hospital-Home Fecal Microbiota Transplantation via Percutaneous Endoscopic Cecostomy for Recurrent Steroid-Dependent Ulcerative Colitis. <i>Gut and Liver</i> , <b>2016</b> , 10, 975-980	4.8	9
22	Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life. <i>Gut and Liver</i> , <b>2017</b> , 11, 370-376	4.8	18
21	Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. <i>Intestinal Research</i> , <b>2019</b> , 17, 349-356	4.1	4
20	Medication adherence initiatives [Part II. <i>Canadian Pharmacists Journal</i> , <b>2007</b> , 140, 320-325	1.3	
19	M. <b>2007</b> , 211-241		
18	A. <b>2007</b> , 1-31		
17	Step-Up Versus Top-Down Therapy in Ulcerative Colitis. <b>2014</b> , 457-467		
16	Abdominosacral Resection for Rectal Cancer. <b>2015</b> , 139-157		
15	The complexity of evaluating and increasing adherence in inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2017</b> , 109, 539-541	0.9	0

14	Chemopreventive effect of aminosalicylates. 151-158		
13	The multimatrix mesalamine formulation. <i>Gastroenterology and Hepatology</i> , <b>2007</b> , 3, 288	0.7	
12	Overcoming adherence issues in ulcerative colitis. <i>Gastroenterology and Hepatology</i> , <b>2007</b> , 3, 795-9	0.7	6
11	A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , <b>2020</b> , 16, 21-27	0.7	
10	Foundations of gastrointestinal-based drug delivery and future developments. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	4
9	DEMATEL Analysis of Medication Non-Adherence Behavior of Patients. <i>International Journal of Reliable and Quality E-Healthcare</i> , <b>2022</b> , 11, 1-22	0.4	
8	Anti-Inflammatory, Antioxidant, and Healing-Promoting Effects of Extract in the Experimental Colitis in Rats.. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2021</b> , 2021, 9945244	2.3	3
7	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	0
6	Amelioration of DSS-Induced Acute Colitis in Mice by Recombinant Monomeric Human Interleukin-22. <i>Immune Network</i> , <b>2022</b> , 22,	6.1	0
5	Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors. <b>2022</b> , 45, 35-45		
4	Rubia cordifolia L. ameliorates DSS-induced ulcerative colitis in mice through dual inhibition of NLRP3 inflammasome and IL-6/JAK2/STAT3 pathways. <b>2022</b> , e10314		0
3	Targeted colonic release formulations of mesalazine I A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis. <b>2022</b> , 625, 122055		1
2	Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study. Publish Ahead of Print,		0
1	How to Improve Your Success in Treating Mild and Moderate Inflammatory Bowel Disease. 2-9		0